Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 0%
Buy 13%
Hold 88%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is in a strong position, as both its technology and professional services segments continue to drive revenue growth, with a particular focus on expanding up-market and leveraging advancements in AI and Ignite intelligence. However, challenges in the end market and a negative mix shift towards services could act as near-term headwinds, as well as a potential slowdown in M&A activity. Despite these risks, Health Catalyst has a strong track record of customer retention and the company is taking steps to effectively communicate its value proposition through new leadership, making it a promising investment opportunity in the healthcare data and analytics space.

Bears say

Health Catalyst is facing significant challenges due to its ongoing transformation and recent divestiture of Vitalware, leading to a decline in revenue and adjusted EBITDA in FY26. The company's FY26 guidance also reflects a high level of churn and down-sell risk among its DOS (Data Operating System) clients, making it difficult to predict future performance. Additionally, while the company is implementing cost-saving measures through its Project Nexus initiative, there is a risk of execution issues as they navigate the transformation. This, coupled with uncertainties surrounding the current business model and lack of clarity on future growth prospects, leads to a cautious outlook on the stock.

HCAT has been analyzed by 8 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 13% recommend Buy, 88% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 8 analysts, HCAT has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.